WO2007094495A3 - 新規な抗がんカテプシン製剤およびそれを用いたがん併用療法抗がん剤 - Google Patents

新規な抗がんカテプシン製剤およびそれを用いたがん併用療法抗がん剤 Download PDF

Info

Publication number
WO2007094495A3
WO2007094495A3 PCT/JP2007/052966 JP2007052966W WO2007094495A3 WO 2007094495 A3 WO2007094495 A3 WO 2007094495A3 JP 2007052966 W JP2007052966 W JP 2007052966W WO 2007094495 A3 WO2007094495 A3 WO 2007094495A3
Authority
WO
WIPO (PCT)
Prior art keywords
anticancer
cathepsin
anticancer agent
preparation
sensitivity
Prior art date
Application number
PCT/JP2007/052966
Other languages
English (en)
French (fr)
Other versions
WO2007094495A2 (ja
Inventor
Kenji Yamamoto
Tomoyo Kawakubo
Original Assignee
Univ Kyushu Nat Univ Corp
Kenji Yamamoto
Tomoyo Kawakubo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyushu Nat Univ Corp, Kenji Yamamoto, Tomoyo Kawakubo filed Critical Univ Kyushu Nat Univ Corp
Priority to US12/279,427 priority Critical patent/US20100047227A1/en
Priority to EP07714492A priority patent/EP2027871A4/en
Priority to JP2008500586A priority patent/JPWO2007094495A1/ja
Publication of WO2007094495A2 publication Critical patent/WO2007094495A2/ja
Publication of WO2007094495A3 publication Critical patent/WO2007094495A3/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　この発明の抗がんカテプシン製剤は、カテプシンＥおよび／またはその活性部位からなるもしくはその活性部位を含む活性フラグメントを有効成分として含有する。 　この発明の抗がんカテプシン製剤は、正常細胞に対しては悪影響を及ぼすことなく、がん細胞のみの成長を阻止ならびに転移を防止すると共に、がん細胞のアポトーシスを誘導することができる。また、他の抗がん剤と併用することにより、従来の抗がん剤が感受性を示さなかったがんに対しても、その感受性を増強することができ、その感受性増強作用によりがんに対する治療効果を著しく高めることができる。さらに、抗がん剤の感受性が増強されることにより、その抗がん剤自体の用量を減少することができることになり、その抗がん剤による副作用などを著しく低減することができる。
PCT/JP2007/052966 2006-02-17 2007-02-19 新規な抗がんカテプシン製剤およびそれを用いたがん併用療法抗がん剤 WO2007094495A2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/279,427 US20100047227A1 (en) 2006-02-17 2007-02-19 Novel anticancer cathepsin formulations and anticancer agent for use in combined anticancer therapy
EP07714492A EP2027871A4 (en) 2006-02-17 2007-02-19 NEW CATHEPSIN PREPARATION AGAINST CANCER AND THIS USING CANCER FOR COMBINATION THERAPY AGAINST CANCER
JP2008500586A JPWO2007094495A1 (ja) 2006-02-17 2007-02-19 新規な抗がんカテプシン製剤およびそれを用いたがん併用療法抗がん剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-040447 2006-02-17
JP2006040447 2006-02-17

Publications (2)

Publication Number Publication Date
WO2007094495A2 WO2007094495A2 (ja) 2007-08-23
WO2007094495A3 true WO2007094495A3 (ja) 2007-10-11

Family

ID=38371906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/052966 WO2007094495A2 (ja) 2006-02-17 2007-02-19 新規な抗がんカテプシン製剤およびそれを用いたがん併用療法抗がん剤

Country Status (5)

Country Link
US (1) US20100047227A1 (ja)
EP (1) EP2027871A4 (ja)
JP (1) JPWO2007094495A1 (ja)
CN (1) CN101384277A (ja)
WO (1) WO2007094495A2 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101693110B1 (ko) 2015-05-07 2017-01-05 계명대학교 산학협력단 카뎁신 b 억제제 또는 카뎁신 d 억제제와 트레일을 유효성분으로 함유하는 암 예방 또는 치료용 조성물

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016199437A1 (ja) * 2015-06-12 2016-12-15 株式会社ソシオネクスト 半導体装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0658939A (ja) * 1992-08-06 1994-03-04 Tosoh Corp 癌の診断方法および医薬品組成物
JP2005117993A (ja) * 2003-10-20 2005-05-12 Sangaku Renkei Kiko Kyushu:Kk カテプシンｅの腫瘍マーカーとしての用途およびカテプシンｅならびにカテプシンｄの腫瘍血管新生阻害療法のターゲットとしての用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05252961A (ja) * 1991-08-06 1993-10-05 Tosoh Corp ヒトカテプシンｅの製造法
WO2000023096A2 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Combination therapy with vip antagonist
WO2001008698A1 (fr) 1999-07-30 2001-02-08 Hisamitsu Pharmaceutical Co., Inc. Agents de potentialisation de compositions chimiotherapiques, anticancereuses et procede de potentialisation de ces substances
JP2004026811A (ja) 2002-04-30 2004-01-29 Kiyoshi Hashizume ビタミンｄ３誘導体を含有する抗癌作用を増強させるための薬剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0658939A (ja) * 1992-08-06 1994-03-04 Tosoh Corp 癌の診断方法および医薬品組成物
JP2005117993A (ja) * 2003-10-20 2005-05-12 Sangaku Renkei Kiko Kyushu:Kk カテプシンｅの腫瘍マーカーとしての用途およびカテプシンｅならびにカテプシンｄの腫瘍血管新生阻害療法のターゲットとしての用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DE J.: "Noncaspase proteases in apoptosis", LEUKEMIA, vol. 14, 2000, pages 1695 - 1703, XP003024618 *
PITTI R.M. ET AL.: "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 22, 1996, pages 12687 - 12690, XP003024616 *
WILEY S.R. ET AL.: "Identification and characterization of a new member of the TNF family that induces apoptosis", IMMUNITY, vol. 3, December 1995 (1995-12-01), pages 673 - 682, XP003024617 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101693110B1 (ko) 2015-05-07 2017-01-05 계명대학교 산학협력단 카뎁신 b 억제제 또는 카뎁신 d 억제제와 트레일을 유효성분으로 함유하는 암 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
JPWO2007094495A1 (ja) 2009-07-09
US20100047227A1 (en) 2010-02-25
EP2027871A2 (en) 2009-02-25
WO2007094495A2 (ja) 2007-08-23
CN101384277A (zh) 2009-03-11
EP2027871A4 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
WO2007126832A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
WO2005032474A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
EP2045251A4 (en) COMPOUNDS WHICH CAN INCLUDE THE UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
WO2006044421A3 (en) Cardiac safe, rapid medication delivery
WO2010110685A8 (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
EP3241840A3 (en) Inhibition of axl signaling in anti-metastatic therapy
PT1778680E (pt) Derivados espirocíclicos de ciclo-hexano
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
GB0524958D0 (en) Transdermal administration of active agents
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
CR10305A (es) "derivados sustituidos de cromanol y su uso.
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2007128564A3 (en) Use of a compound with rankl activity
WO2009088673A3 (en) Pharmaceutical composition
EP2481428A3 (en) MMP activated vascular disrupting agents
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008500586

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200780005718.8

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007714492

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12279427

Country of ref document: US